07:32 AM EDT, 09/16/2024 (MT Newswires) -- NuCana ( NCNA ) shares were up 200% pre-bell Monday after the company said that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.

Dermata Therapeutics ( DRMA ) stock was over 64% higher following a 6.8% rise in the previous session.

Exicure ( XCUR ) shares were up 43%, adding to Friday's 5.3% increase.

Agape ATP ( ATPC ) stock was 26% higher, extending Friday's rally.

Nuvalent ( NUVL ) shares were up nearly 16% after Friday's 7.1% rise.

Price: 7.6200, Change: +5.08, Percent Change: +200.00